PMV PHARMACEUTICALS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
PMV PHARMACEUTICALS, INC. (PMVP) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $1.51 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-14
- PMV PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $1.53, a 15.91% increase year-over-year.
- PMV PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $1.32, a 26.26% decline year-over-year.
- PMV PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $1.79, a 77.76% decline year-over-year.
- PMV PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $8.05, a 50.91% decline year-over-year.
- PMV PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $1.29, a 21.34% decline from fiscal 2024.
- PMV PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $1.64, a 71.92% decline from fiscal 2023.
- PMV PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $5.84, a 63.11% decline from fiscal 2022.
- PMV PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $15.83, a 45.82% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $1.51 10-Q · filed 2026-08-14 | ||||
| 2026-03-31 | $1.53 10-Q · filed 2026-05-12 | ||||
| 2025-12-31 | $1.29 10-K · filed 2026-03-06 | ||||
| 2025-09-30 | $1.29 10-Q · filed 2025-11-12 | ||||
| 2025-06-30 | $1.29 10-Q · filed 2025-08-07 | ||||
| 2025-03-31 | $1.32 10-Q · filed 2025-05-09 | ||||
| 2024-12-31 | $1.64 10-K · filed 2025-03-03 | ||||
| 2024-09-30 | $1.64 10-Q · filed 2024-11-07 | ||||
| 2024-08-13 | $1.48 DEF 14A · filed 2026-04-22 | ||||
| 2024-06-30 | $1.78 10-Q · filed 2024-08-08 | ||||
| 2024-03-31 | $1.79 10-Q · filed 2024-05-09 | ||||
| 2023-12-31 | $5.84 10-K · filed 2024-02-29 | ||||
| 2023-09-30 | $5.83 10-Q · filed 2023-11-09 | ||||
| 2023-06-30 | $5.76 10-Q · filed 2023-08-09 | ||||
| 2023-03-31 | $8.05 10-Q · filed 2023-05-10 | ||||
| 2022-12-31 | $15.83 10-K · filed 2023-03-01 | ||||
| 2022-09-30 | $16.28 10-Q · filed 2022-11-08 | ||||
| 2022-06-30 | $16.33 10-Q · filed 2022-08-09 | ||||
| 2022-03-31 | $16.40 10-Q · filed 2022-05-10 | ||||
| 2021-12-31 | $29.22 10-K · filed 2022-03-01 | ||||
| 2021-09-30 | $30.03 10-Q · filed 2021-11-12 | ||||
| 2021-06-30 | $30.03 10-Q · filed 2021-08-13 | ||||
| 2021-03-31 | $34.30 10-Q · filed 2021-05-14 | ||||
| 2020-12-31 | $5.23 10-K · filed 2021-03-03 | ||||
| 2020-09-30 | $4.49 10-Q · filed 2020-11-13 | ||||
| 2019-12-31 | $3.53 10-K · filed 2021-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |